Gene Therapy for Blindness Caused by Choroideremia

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

October 31, 2017

Study Completion Date

October 31, 2017

Conditions
Choroideremia
Interventions
DRUG

rAAV2.REP1

Single subretinal injection of rAAV2.REP1 vector suspension containing 10e12 genome particles per ml. Dose 1 = dose containing approximately 10e10 rAAV2.REP1 genome particles. Dose 2 = dose containing approximately 10e11 rAAV2.REP1 genome particles.

Trial Locations (4)

EC1V 2PD

Moorfields Eye Hospital NHS Foundation Trust, London

M13 9WL

St Mary's Hospital, Central Manchester University Hospitals NHS Foundation Trust, Manchester

OX3 9DU

Oxford Radcliffe Hospitals NHS Trust, Oxford

SO16 6YD

Eye Unit, Southampton University Hospitals NHS Trust, Southampton

All Listed Sponsors
collaborator

Oxford University Hospitals NHS Trust

OTHER

collaborator

Moorfields Eye Hospital NHS Foundation Trust

OTHER

collaborator

University College, London

OTHER

collaborator

Manchester University NHS Foundation Trust

OTHER_GOV

collaborator

University of Manchester

OTHER

collaborator

University Hospital Southampton NHS Foundation Trust

OTHER

collaborator

University of Southampton

OTHER

lead

University of Oxford

OTHER

NCT01461213 - Gene Therapy for Blindness Caused by Choroideremia | Biotech Hunter | Biotech Hunter